Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)

This site was designed to provide you with information about PRO-CTCAE®, a patient-reported outcome measurement system developed by the National Cancer Institute to capture symptomatic adverse events in patients on cancer clinical trials. The availability of PRO-CTCAE in more than 60 validated languages supports the inclusion of culturally and linguistically diverse populations in cancer clinical trials and addresses language-related barriers to the equitable participation of underrepresented groups.

More About PRO-CTCAE
PRO-CTCAE logo

Announcements

  • We have recently finalized a set of data standards for PRO-CTCAE. More information about these standards, which were developed in collaboration with Clinical Data Interchange Standards Consortium (CDISC) and the US FDA, is available on the CDISC websiteExternal Web Site Policy and the PRO-CTCAE Frequently Asked Questions.
  • The Ped-PRO-CTCAE module is now available in French (for France and Belgium) and in French (for Canada). The availability of these two new language versions allows for the capture of symptomatic adverse events from French-speaking children and their caregiver proxies.
Last Updated: 17 Jan, 2025